Fired Canopy Development CEO Bruce Linton bounces back with new roles


As soon as the face of the Canadian cannabis organization, the former Canopy Development chief executive Bruce Linton is producing a comeback in the sector.

This week, Linton announced he is taking on new roles with two corporations in the sector, as properly as a directorial position at an Australian organization that operates with psychedelic-primarily based treatment options for mental illnesses.

“You cannot remedy entrepreneurs,” he told Bloomberg, explaining that following his ousting at Canopy Development, he spent the summer time seeking for new possibilities.

In his pursuit of a “stable organization,” Linton chosen Florida-primarily based animal wellness and CBD firm Improved Decision, exactly where he will enable with its CBD study efforts. The news of Linton joining Improved Decision sent the company’s stock soaring more than 20%.

Meanwhile, the co-founder of Canopy Development, who was fired more than the company’s disappointing earnings, will also serve as executive chairman at Massachusetts recreational marijuana dispensary Gage Cannabis Co.

Due to Linton signing a non-compete clause as portion of his termination with Canopy, the businessman is not permitted to function for Canadian cannabis corporations.

Gage not too long ago entered an exclusive partnership in Michigan with marijuana startup Cookies, a move which Linton told Bloomberg will position the firm as a “dominant player” in the state.

Linton’s third new venture, Thoughts Medicine Inc., is oriented towards the therapeutic possible of psychedelics like psilocybin.

According to the company’s site, Thoughts Medicine “is looking for to establish secure and powerful psychedelic-assisted treatment options for mental illness in Australia. As a registered charity (DGR-1 status), we are supporting clinical study and functioning towards regulatory-authorized and proof-primarily based psychedelic-assisted therapies.”

In the United States, interest in this aspect of hallucinogenic drugs culminated in the launching of a new study center at John Hopkins Medicine not too long ago.

“The way I chosen the corporations was not how a lot equity they would give me. I turned down the most self-enriching provides. Nevertheless, to be transparent, all firms offered me with generous equity exposure. With every firm and space, I sought to create a particular view of how we make enterprise worth from the present activities and limit disruption,” Linton stated in a distinctive interview with Yahoo Finance on Tuesday.


Latest posts